Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): final results of a randomised phase 3 study
Thomas Yau, Ahmed O. Kaseb, Ann‐Lii Cheng, Shukui Qin, Andrew X. Zhu, Stephen L. Chan, Tamar Melkadze, Wattana Sukeepaisarnjaroen, Valery Breder, Gontran Verset, Edward Gane, Ivan Borbath, Jose David Gomez Rangel, Baek‐Yeol Ryoo, Tamta Makharadze, Philippe Merle, Fawzi Benzaghou, Steven Milwee, Zhong Wang, Dominic Curran, Robin Kate Kelley, Lorenza Rimassa
Topics & Concepts
AtezolizumabSorafenibCabozantinibHepatocellular carcinomaMedicineOncologyInternal medicinePembrolizumabCancerImmunotherapyHepatocellular Carcinoma Treatment and PrognosisCholangiocarcinoma and Gallbladder Cancer StudiesLiver physiology and pathology